Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs

Atopic dermatitis (AD) represents the most common skin disease characterized by heterogeneous endophenotypes and a high disease burden. In Europe, six new systemic therapies for AD have been approved: the biologics dupilumab (anti‐interleukin‐4 receptor (IL‐4R) α in 2017), tralokinumab (anti‐IL‐13 i...

Full description

Saved in:

Bibliographic Details
Published in:	Allergy (Copenhagen) Vol. 79; no. 6; pp. 1501 - 1515
Main Authors:	Müller, Svenja, Maintz, Laura, Bieber, Thomas
Format:	Journal Article
Language:	English
Published:	Denmark Blackwell Publishing Ltd 01.06.2024
Subjects:	Atopic dermatitis biological therapy Cardiovascular diseases Clinical trials Dermatitis Drug development drug therapy Inhibitor drugs Janus kinase Malignancy Mesenchymal stem cells Monoclonal antibodies Neurokinin Opioid receptors Ox40L protein Precision medicine Skin diseases Thromboembolism Transient receptor potential proteins Tumor necrosis factor drug development atopic dermatitis precision medicine drug therapy biological therapy
ISSN:	0105-4538, 1398-9995, 1398-9995
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!